These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 16000576)

  • 1. Immunologic purging of autologous peripheral blood stem cell products based on CD34 and CD133 expression can be effectively and safely applied in half of the acute myeloid leukemia patients.
    Feller N; van der Pol MA; Waaijman T; Weijers GW; Westra G; Ossenkoppele GJ; Schuurhuis GJ
    Clin Cancer Res; 2005 Jul; 11(13):4793-801. PubMed ID: 16000576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positive selection for CD90 as a purging option in acute myeloid leukemia stem cell transplants.
    Feller N; Kelder A; Westra G; Ossenkoppele GJ; Schuurhuis GJ
    Cytometry B Clin Cytom; 2008 Jan; 74(1):9-16. PubMed ID: 18061946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A combination of CD34 selection and complement-mediated immunopurging (anti-CD15 monoclonal antibody) eliminates tumor cells while sparing normal progenitor cells.
    Nimgaonkar M; Kemp A; Lancia J; Ball ED
    J Hematother; 1996 Feb; 5(1):39-48. PubMed ID: 8646480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ex vivo expansion of normal progenitor cells from acute myeloid leukemia cell-contaminated CD34+ peripheral blood progenitor cells after mafosfamide purging.
    Stilz R; Grünebach F; Bader P; Vogel W; Kanz L; Brugger W; Scheding S
    J Hematother Stem Cell Res; 2001 Dec; 10(6):777-85. PubMed ID: 11798504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping.
    Wuchter C; Ratei R; Spahn G; Schoch C; Harbott J; Schnittger S; Haferlach T; Creutzig U; Sperling C; Karawajew L; Ludwig WD
    Haematologica; 2001 Feb; 86(2):154-61. PubMed ID: 11224484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of AC133 vs. CD34 in acute childhood leukemias].
    Ebener U; Brinkmann A; Zotova V; Niegemann E; Wehner S
    Klin Padiatr; 2000; 212(3):90-8. PubMed ID: 10916777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AC133 expression on acute myeloid leukemia blasts: correlation to FAB and to CD34 expression and possible implications for peripheral blood progenitor cell purging in AML.
    Fauth F; Weidmann E; Martin H; Schneider B; Sonnhoff S; Hoelzer D
    Leuk Res; 2001 Mar; 25(3):191-6. PubMed ID: 11226513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive selection and transplantation of autologous highly purified CD133(+) stem cells in resistant/relapsed chronic lymphocytic leukemia patients results in rapid hematopoietic reconstitution without an adequate leukemic cell purging.
    Isidori A; Motta MR; Tani M; Terragna C; Zinzani P; Curti A; Rizzi S; Taioli S; Giudice V; D'Addio A; Gugliotta G; Conte R; Baccarani M; Lemoli RM
    Biol Blood Marrow Transplant; 2007 Oct; 13(10):1224-32. PubMed ID: 17889360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcome.
    Feller N; Schuurhuis GJ; van der Pol MA; Westra G; Weijers GW; van Stijn A; Huijgens PC; Ossenkoppele GJ
    Leukemia; 2003 Jan; 17(1):68-75. PubMed ID: 12529662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD133-2 (AC141) expression analysis in acute leukemia immunophenotyping in correlation to CD34 and P-glycoprotein.
    Guenova M; Balatzenko G
    Hematology; 2008 Jun; 13(3):137-41. PubMed ID: 18702870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purging of peripheral blood stem cell transplants in AML: a predictive model based on minimal residual disease burden.
    Feller N; Jansen-van der Weide MC; van der Pol MA; Westra GA; Ossenkoppele GJ; Schuurhuis GJ
    Exp Hematol; 2005 Jan; 33(1):120-30. PubMed ID: 15661405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viable CD34+/CD133+ blood progenitor cell dose as a predictor of haematopoietic engraftment in multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation.
    Hicks C; Wong R; Manoharan A; Kwan YL
    Ann Hematol; 2007 Aug; 86(8):591-8. PubMed ID: 17492259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proliferation and differentiation potential of CD133+ and CD34+ populations from the bone marrow and mobilized peripheral blood.
    Koutna I; Peterkova M; Simara P; Stejskal S; Tesarova L; Kozubek M
    Ann Hematol; 2011 Feb; 90(2):127-37. PubMed ID: 20821012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD45
    Heo SK; Noh EK; Ju LJ; Sung JY; Jeong YK; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
    BMC Cancer; 2020 Apr; 20(1):285. PubMed ID: 32252668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison between three graft manipulation methods for haploidentical stem cell transplantation in pediatric patients: preliminary results of a pilot study.
    Lang P; Schumm M; Greil J; Bader P; Klingebiel T; Müller I; Feuchtinger T; Pfeiffer M; Schlegel PG; Niethammer D; Handgretinger R
    Klin Padiatr; 2005; 217(6):334-8. PubMed ID: 16307419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD133+CD34+ and CD133+CD38+ blood progenitor cells as predictors of platelet engraftment in patients undergoing autologous peripheral blood stem cell transplantation.
    Camacho Villa AY; Reyes Maldonado E; Montiel Cervantes LA; Vela Ojeda J
    Transfus Apher Sci; 2012 Jun; 46(3):239-44. PubMed ID: 22386660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD133 allows elaborated discrimination and quantification of haematopoietic progenitor subsets in human haematopoietic stem cell transplants.
    Radtke S; Görgens A; Kordelas L; Schmidt M; Kimmig KR; Köninger A; Horn PA; Giebel B
    Br J Haematol; 2015 Jun; 169(6):868-78. PubMed ID: 25819405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDCP1 identifies a broad spectrum of normal and malignant stem/progenitor cell subsets of hematopoietic and nonhematopoietic origin.
    Bühring HJ; Kuçi S; Conze T; Rathke G; Bartolović K; Grünebach F; Scherl-Mostageer M; Brümmendorf TH; Schweifer N; Lammers R
    Stem Cells; 2004; 22(3):334-43. PubMed ID: 15153610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative analysis of proliferative potential and clonogenicity of MACS-immunomagnetic isolated CD34+ and CD133+ blood stem cells derived from a single donor.
    Freund D; Oswald J; Feldmann S; Ehninger G; Corbeil D; Bornhäuser M
    Cell Prolif; 2006 Aug; 39(4):325-32. PubMed ID: 16872366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combination of anti-CD15 monoclonal antibody PM-81 and 4-hydroperoxycyclophosphamide augments tumor cytotoxicity while sparing normal progenitor cells.
    Rubin J; Malley V; Ball ED
    J Hematother; 1994; 3(2):121-7. PubMed ID: 7922015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.